NASDAQ:IMGN - ImmunoGen, Inc.
$5.68
 $0.19
+3.46%
2:20PM EDT
2019-02-15
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  IMGN     avg for
industry  
  avg for
sector  
42 stocks weight:  24. 56   0. 00   0. 00  
42 stocks rank:  3. 51 K 1. 86 K 1. 09 K
# analyst opinions:  8. 00   14. 92   14. 43  

quick ratio:  3. 74   5. 37   1. 81  
current ratio:  3. 74   5. 69   2. 19  

target price low:  3. 00   88. 97   117. 82  
target price avg:  14. 63   115. 19   141. 96  
target price high:  6. 37   143. 40   163. 16  
1-yr high:  12. 95   124. 30   142. 77  
last close:  5. 49   101. 85   127. 84  
50-day avg:  5. 09   98. 27   122. 46  
200-day avg:  8. 03   99. 72   122. 70  
1-yr low:  3. 94   78. 19   100. 16  
volume:  1. 65 M 2. 38 M 4. 64 M
50-day avg volume:  2. 50 M 3. 31 M 4. 94 M
200-day avg volume:  2. 37 M 3. 23 M 4. 28 M

1-day return:  0. 55 % 0. 22 % 0. 48 %
this week return:  -3. 17 % 1. 77 % 2. 01 %
12-wk return:  -0. 72 % 6. 56 % 3. 33 %
52-wk return:  -48. 73 % -2. 23 % 14. 35 %

enterprise value (EV):  541. 94 M 55. 17 B 104. 51 B
market cap:  818. 51 M 49. 01 B 96. 46 B
EBITDA:  -148. 53 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -3. 65   -91. 79   2. 29  
enterprise/revenue (EV/R):  10. 07   29. 84   23. 39  
total revenue:  53. 82 M 11. 28 B 40. 22 B
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -167. 87 M 2. 37 B 3. 58 B

shares outstanding:  149. 09 M 607. 99 M 1. 22 B
shares:  133. 42 M 605. 53 M 1. 15 B
shares short:  14. 51 M 11. 62 M 12. 55 M
shares short prior month:  13. 51 M 11. 95 M 13. 44 M
short ratio:  4. 94   4. 82   3. 10  
short % of float:  11. 15 % 6. 19 % 2. 82 %
total cash/share:  1. 78   12. 02   11. 46  
total cash:  262. 25 M 7. 41 B 7. 37 B

book value:  0. 08   14. 43   28. 26  
price/book:  67. 78   -1. 57   -2. 97  
gross profits:  -120. 07 M 8. 28 B 18. 09 B
operating margins:  -291. 34 % -458. 01 % -642. 83 %
EBITDA margins:  -276. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  -223. 11 % 49. 33 % 54. 53 %

1-yr max volatility:  -16. 02 % --- ---
1-yr mean volatility:  -0. 15 % 0. 01 % 0. 06 %

1-yr EPS:  -1. 20   3. 03   4. 09  
forward EPS:  -1. 19   4. 33   6. 99  
P/E:  -4. 58   6. 11   26. 91  
forward P/E:  -4. 61   8. 38   10. 48  
PE/G:  0. 07   0. 37   5. 61  
growth:  -65. 10 % 683. 72 % 104. 79 %
earnings high:  -0. 25   1. 27   1. 66  
earnings avg:  -0. 32   1. 01   1. 53  
earnings low:  -0. 36   0. 76   1. 40  
revenue high:  15. 34 M 2. 86 B 11. 19 B
revenue avg:  12. 27 M 2. 78 B 10. 84 B
revenue low:  10. 50 M 2. 67 B 10. 64 B
return on assets:  -33. 19 % -3. 27 % 3. 81 %
revenue growth:  -65. 10 % 648. 36 % 97. 70 %
revenue/share:  0. 39   14. 68   59. 83  

beta (1yr vs S&P500):  1. 75   1. 21   0. 93  
sharpe (1yr):  -0. 58   0. 06   0. 98  

held % insiders:  1. 64 % 6. 46 % 3. 21 %
held % institutions:  85. 32 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : IMGN
.    + 1.143 =         1.143 :: INITIAL WEIGHT
.  + 294.297 =        295.44 :: inverse volume-to-price addition
.  + 208.249 =       503.689 :: spline projection addition
.  - 170.205 =       333.485 :: poor performance penalty
.    x 0.728 =       242.841 :: one-year gains+dividend factor
.    x 7.671 =      1862.921 :: 13 weeks' performance factor
.    x 1.492 =      2780.388 :: industry recommendation factor
.    x 1.338 =      3718.803 :: EV/R factor
.    x 0.997 =       3706.46 :: return on assets factor
.    x 0.993 =      3682.331 :: revenue growth factor
.    x 2.657 =      9785.458 :: current ratio factor
.    x 1.168 =      11430.84 :: quick ratio factor
.    x 1.097 =     12534.526 :: short ratio factor
.    x 2.941 =     36869.399 :: price-to-book factor
.    x 1.091 =     40222.479 :: 5-day avg > 50-day avg
.    x 2.147 =     86369.507 :: P/E weight
.    x 1.942 =    167748.217 :: PE/G factor
.    x 1.454 =    243945.102 :: beta factor
.     x 0.58 =    141607.123 :: sharpe factor
.    x 0.933 =    132070.412 :: target low factor
.     x 1.43 =    188873.403 :: target mean factor
.     x 1.04 =    196418.863 :: target high factor
.    x 1.066 =    209306.456 :: industry 12-weeks return
.    x 0.932 =    195058.174 :: "drift" penalty 1 days ago
.    x 0.891 =    173737.333 :: "drift" penalty 3 days ago
.    x 0.998 =    173321.817 :: overall "drift" factor
.    x 0.999 =    173205.181 :: largest single-day jump factor
.    x 0.086 =     14816.525 :: low price factor
.      x 1.0 =      14817.52 :: factor hist industry gain for week 06
.   cubeRoot =        24.562 :: reduced for readability
.                     24.562 :: FINAL WEIGHT for NASDAQ:IMGN


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org